Company intelligence / Profile preview

IMPACTx10

Ownership: Private
Development stage: Other

Overview

ImPact Biotech’s lead program, Padeliporfin VTP, has received FDA Orphan Drug Designation for pancreatic cancer and has shown promising early results in several solid tumor types. The platform aims to provide minimally invasive, surgery-like efficacy while preserving healthy tissue or organs, especially for high-risk surgical patients or those with limited treatment options. Earlier research established safety and efficacy in low-risk prostate cancer; current focus is on expanding indications to other solid tumors such as UTUC, NSCLC, esophageal and pancreatic cancers.

Therapeutic areas: Oncology
Modalities: Small moleculePhotodynamic therapy (Padeliporfin VTP)
Industry: Biotech

Partnerships

Weizmann Institute of Science (Israel) [academic collaboration]Memorial Sloan Kettering Cancer Center (US) [academic collaboration]

Beyond the preview

Go deeper on IMPACTx10.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMPACTx10.

Explore the full profile